Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway

NeuroMolecular Medicine

Volumn 7, Issue 4, 2005, Pages 287-296

  Jozwiak, Jaroslaw ^a   Jozwiak, Sergiusz ^b   Grzela, Tomasz ^a   Lazarczyk, Maciej ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Hamartin; mTOR; Tuberin; Tuberous sclerosis (TSC)

Indexed keywords

ADENYLATE KINASE; CYCLOSPORIN A; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; HAMARTIN; ISOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE LKB1; RAPAMYCIN; RAS PROTEIN; RHEB PROTEIN; S6 KINASE; TACROLIMUS; TUBERIN; UNCLASSIFIED DRUG;

CELL PROLIFERATION; ENVIRONMENTAL FACTOR; ENZYME REGULATION; GENETIC CODE; HYPOXIA; INHIBITION KINETICS; NONHUMAN; OXIDATIVE STRESS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; HUMANS; MAP KINASE SIGNALING SYSTEM; PROTEIN BIOSYNTHESIS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 29244481490     PISSN: 15351084     EISSN: None     Source Type: Journal    
DOI: 10.1385/NMM:7:4:287     Document Type: Review

References (54)

1. Ballif B. A., Roux P. P., Gerber S. A., MacKeigan J. P., Blenis J., and Gygi S. P. (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl. Acad. Sci. USA 102, 667-672.
2. Brugarolas J., Lei K., Hurley R. L., et al. (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18, 2893-2904.
3. Castro A. F., Rebhun J. F., Clark G. J., and Quilliam L. A. (2003) Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278, 32,493-32,496.
4. Cheng S. W., Fryer L. G., Carling D., and Shepherd P. R. (2004) J. Biol. Chem. 279, 15,719-15,722.
5. Corradetti M. N., Inoki K., Bardeesy N., DePinho R. A., and Guan K. L. (2004) Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 18, 1533-1538.
6. Dan H. C., Sun M., Yang L., et al. (2002) Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 277, 35,364-35,370.
7. Ellisen L. W., Ramsayer K. D., Johannessen C. M., et al. (2002) REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol. Cell. 10, 995-1005.
8. European Tuberous Sclerosis Consortium. (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. The European Chromosome 16 Tuberous Sclerosis Consortium. Cell 75, 1305-1315.
9. Fadri M., Daquinag A., Wang S., Xue T., and Kunz J. (2005) The pleckstrin homology domain proteins Slm1 and Slm2 are required for actin cytoskeleton organization in yeast and bind phosphatidylinositol-4,5-bisphosphate and TORC2. Mol. Biol. Cell. 16, 1883-1900.
10. Gao X. and Pan D. (2001) TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 15(11), 1383-1392.
11. Gao X., Zhang Y., Arrazola P., et al. (2002) Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4, 699-704.
12. Grolleau A., Bowman J., Pradet-Balade B., et al. (2002) Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J. Biol. Chem. 277, 22,175-22,184.
13. Han S., Santos T. M., Puga A., et al. (2004) Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res. 64, 812-816.
14. Hara K., Maruki Y., Long X., et al. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 110, 177-189.
15. Ho H. L., Shiau Y. S., and Chen M. Y. (2005) Saccharomyces cerevisiae TSC11/AVO3 participates in regulating cell integrity and functionally interacts with components of the Tor2 complex. Curr. Genet. 47, 273-288.
16. Holz M. K. and Blenis J. (2005) Identification of S6K1 as a novel mTOR-phosphorylating kinase. J. Biol. Chem. (Epub ahead of print).
17. Jacinto E., Loewith R., Schmidt A., et al. (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell. Biol. 6, 1122-1128.
18. Jefferies H. B., Fumagalli S., Dennis P. B., Reinhard C., Pearson R. B., and Thomas G. (1997) Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 16, 3693-3704.
19. Kwiatkowski D. J., Zhang H., Bandura J. L., et al. (2002) A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum. Mol. Genet. 11, 525-534.
20. Li Y., Corradetti M. N., Inoki K., and Guan K. L. (2004) TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29, 32-38.
21. Li Y., Inoki K., and Guan K. L. (2004) Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Mol. Cell. Biol. 24, 7965-7975.
22. Loewith R., Jacinto E., Wullschleger S., et al. (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell. 10, 457-468.
23. Long X., Lin Y., Ortiz-Vega S., Yonezawa K., and Avruch J. (2005) Rheb Binds and Regulates the mTOR Kinase. Curr. Biol. 15, 702-713.
24. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., and Pandolfi P. P. (2005) Phosphorylation and functional inactivation of TSC2 by ERK implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193.
25. Mach K. E., Furge K. A., and Albright C. F. (2000) Loss of Rhb1, a Rheb-related GTPase in fission yeast, causes growth arrest with a terminal phenotype similar to that caused by nitrogen starvation. Genetics 155, 611-622.
26. Maheshwar M. M., Cheadle J. P., Jones A. C., et al. (1997) The GAP-related domain of tuberin, the product of the TSC2 gene, is a target for missense mutations in tuberous sclerosis. Hum. Mol. Genet. 6, 1991-1996.
27. Mayer K., Goedbloed M., van Zijl K., Nellist M., and Rott H. D. (2004) Characterisation of a novel TSC2 missense mutation in the GAP related domain associated with minimal clinical manifestations of tuberous sclerosis. J. Med. Genet. 41, e64.
28. Nellist M., Sancak O., Goedbloed M. A., et al. (2005) Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex. Eur. J. Hum. Genet. 13, 59-68.
29. Nellist M., van Slegtenhorst M. A., Goedbloed M., van den Ouweland A. M., Halley D. J., and van der Sluijs P. (1999) Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin. J. Biol. Chem. 274, 35,647-35,652.
30. Nellist M., Verhaaf B., Goedbloed M. A., Reuser A. J., van den Ouweland A. M., and Halley D. J. (2001) TSC2 missense mutations inhibit tuberin phosphorylation and prevent formation of the tuberin-hamartin complex. Hum. Mol. Genet. 10, 2889-2898.
31. Nojima H., Tokunaga C., Eguchi S., et al. (2003) The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 278, 15,461-15,464.
32. Oshiro N., Yoshino K., Hidayat S., et al. (2004) Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 9, 359-366.
33. Patel P. H., Thapar N., Guo L., et al. (2003) Drosophila Rheb GTPase is required for cell cycle progression and cell growth. J. Cell. Sci. 116, 3601-3610.
34. Pende M., Um S. H., Mieulet V., et al. (2004) S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24, 3112-3124.
35. Plas D. R. and Thompson C. B. (2003) Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem. 278, 12,361-12,366.
36. Reynolds T. H. T., Bodine S. C., and Lawrence J. C., Jr. (2002) J. Biol. Chem. 277, 17,657-17,662.
37. Richardson C. J., Broenstrup M., Fingar D. C., et al. (2004) SKAR is a specific target of S6 kinase 1 in cell growth control. Curr. Biol. 14, 1540-1549.
38. Roux P. P., Ballif B. A., Anjum R., Gygi S. P., and Blenis J. (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. USA 101, 13,489-13,494.
39. Sancak O., Nellist M., Goedbloed M., et al. (2005) Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur. J. Hum. Genet. 47, 273-288.
40. Schalm S. S., Fingar D. C., Sabatini D. M., and Blenis J. (2003) TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 13, 797-806.
41. Schalm S. S., Tee A. R., and Blenis J. (2005) Characterization of a conserved C-terminal (RSPRR) motif in S6K1 required for its mTOR-dependent regulation. J. Biol. Chem. 280, 11,101-11,106.
42. Sekulic A., Hudson C. C., Homme J. L., et al. (2000) Cancer Res. 60, 3504-3513.
43. Shaw R. J., Bardeesy N., Manning B. D., et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99.
44. van Slegtenhorst M., de Hoogt R., Hermans C., et al. (1997) Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277, 805-808.
45. Smith E. M., Finn S. G., Tee A. R., Browne G. J., and Proud C. G. (2005) The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem. 280, 18,717-18,727.
46. Soucek T., Pusch O., Wienecke R., DeClue J. E., and Hengstschlager M. (1997) Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J. Biol. Chem. 272, 29,301-29,308.
47. Tang H., Hornstein E., Stolovich M., et al. (2001) Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol. Cell. Biol. 21, 8671-8683.
48. Tee A. R., Fingar D. C., Manning B. D., Kwiatkowski D. J., Cantley L. C., and Blenis J. (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. USA 99, 13,571-13,576.
49. Tee A. R., Manning B. D., Roux P. P., Cantley L. C., and Blenis J. (2003) Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259-1268.
50. Uhlmann E. J., Li W., Scheidenhelm D. K., Gau C. L., Tamanoi F., and Gutmann D. H. (2004) Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia 47, 180-188.
51. Wang X., Li W., Williams M., Terada N., Alessi D. R., and Proud C. G. (2001) Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J. 20, 4370-4379.
52. Wing L. Y., Chen H. M., Chuang P. C., Wu M. H., and Tsai S. J. (2005) The MTOR-S6K1 but not PI3K-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation. J. Biol. Chem. 280, 19,937-19,947
53. Yamagata K., Sanders L. K., Kaufmann W. E., et al. (1994) Rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein. J. Biol. Chem. 269, 16,333-16,339.
54. 1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Mol. Microbiol. 41, 1339-1347.